In vivo evaluation of the anti-tumoral effect of sunitinib eluting beads in the rabbit VX2 tumor model

Purpose: To study the anti-tumoral effect of sunitinib eluting beads in the rabbit VX2 tumor modelMaterials: VX2 tumor were implanted in the left liver lobe of New-Zealand white rabbits. Seven animals received 0.2ml of DC Beads loaded with 6mg of sunitinb (group 1), 6 animals received 0.2ml of DC Beads (group 2) and 6 animals received NaCl 0.9% intra arterially in the left hepatic artery. One animal in each group was sacrificed at 24 hours and the others were left to survive. Liver enzyme were measured daily. In group 1 plasmatic sunitinib concentration were measured daily by LC MS/MS tandem mass spectroscopy. At day 15 all living animals were sacrficed. After sacrifice, or premature euthanasia the livers were harvested for determination of the VEGF receptor tyrosine kinase activity by western blot and histopathological examination.Results: In group 1, no animal died during follow-up. In group 2 and 3, respectively 2 and 3 animals died during follow-up. In group 1 plasmatic sunitinib level remained under therapeutic concentration during the whole experiment. There was an evident lack of phosphorylation of the RTK In group 1 and there was an augmentation of the RTK phosphorylation in group 2 at 24 hours. No difference in RTK activity was noticable at 15 days. From the histopathological point of view it was unpossible to differentiate treatment induced from spontaneous necrosis of tumors.Conclusions: Administration of sunitinib eluting Beads in VX2 carrying rabbits inhibits the activation of RTK's triggered by ischemia. It also seems to prolong survival of the treated animals.

Correction of aberration in holographic optical tweezers using a Shack-Hartmann sensor

Optical aberration due to the nonflatness of spatial light modulators used in holographic optical tweezers significantly deteriorates the quality of the trap and may easily prevent stable trapping of particles. We use a Shack-Hartmann sensor to measure the distorted wavefront at the modulator plane; the conjugate of this wavefront is then added to the holograms written into the display to counteract its own curvature and thus compensate the optical aberration of the system. For a Holoeye LC-R 2500 reflective device, flatness is improved from 0.8¿ to ¿/16 (¿=532 nm), leading to a diffraction-limited spot at the focal plane of the microscope objective, which makes stable trapping possible. This process could be fully automated in a closed-loop configuration and would eventually allow other sources of aberration in the optical setup to be corrected for.

Plasticity of protein expression during culture of fetal skin cells.

In order to gain insight into the biology of fetal skin during culture, cellular proteins were studied during four culture passages (P00, P01, P04 as well as P10) using high-resolution two-dimensional (2-D) gel electrophoresis and mass spectrometry (MS). Bioinformatic analyses were focused on a region of each gel corresponding to pI between 4 and 8 and M(r) from 8000 to 35 000. In this area, 373 +/- 42 spots were detected (N = 18). Twenty-six spots presented an integrated intensity that increased in the higher passages, whereas five spots showed a progressively lower intensity in subsequent passaging. MS analysis was performed on spots that were unambiguously identified on preparative 2-D gels. Among the 26 spots showing an increased size between P00 and P10, 9 were identified, and corresponded to 3 proteins: (i) peptidyl-prolyl cis-trans isomerase A (P05092; cyclophilin A or cyclosporin A-binding protein), (ii) triosephosphate isomerase (P00938), and (iii) enoyl-CoA hydratase (P30084). Among these nine identified spots, three were absent at P00, but were present at P10. They corresponded to isoforms of peptidyl-prolyl cis-trans isomerase and triosephosphate isomerase, respectively. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analyses of the acidic isoforms of triosephosphate isomerase showed modifications of cysteine residues to cysteic acid. All these isoforms were clearly present in the skin cells of a 4-year-old child, as well as in skin cells from a 80-year-old man, at P00. These observations probably reflect either an oxidative stress related to cell culture, or, alternatively, maturation, differentiation and the aging of the cells.

Regulation and glucocorticoid-independent induction of lipocortin I in cultured astrocytes.

Stimulation of prostaglandin (PG) release in rat astroglial cultures by various substances, including phorbol esters, melittin, or extracellular ATP, has been reported recently. It is shown here that glucocorticoids (GCs) reduced both basal and stimulated PGD2 release. Hydrocortisone, however, did not inhibit ATP-, calcium ionophore A23187-, or tetradecanoyl phorbol acetate (TPA)-stimulated arachidonic acid release, and only TPA stimulations were affected by dexamethasone. GC-mediated inhibition of PGD2 release thus appeared to exclude regulation at the phospholipase A2 (PLA2) level. Therefore, the effects of GCs on the synthesis of lipocortin I (LC I), a potent, physiological inhibitor of PLA2, were studied in more detail. Dexamethasone was not able to enhance de novo synthesis of LC I in freshly seeded cultures and failed to increase LC I synthesis in 2-3-week-old cultures. It is surprising that LC I was the major LC synthesized in those cultures, and marked amounts accumulated with culture time, reaching plateau levels at approximately day 10. In contrast, LC I was barely detectable in vivo. This tonic inhibition of PLA2 is the most likely explanation for unsuccessful attempts to evoke PG release in astrocyte cultures by various physiological stimuli. GC receptor antagonists (progesterone and RU 38486) given throughout culture time reduced LC I accumulation and simultaneously increased PGD2 release. Nonetheless, a substantial production of LC I persisted in the presence of antagonists. Therefore, LC I induction did not seem to involve GC receptor activation. This was confirmed in serum- and GC-free brain cell aggregate cultures. Here also a marked accumulation of LC I was observed.(ABSTRACT TRUNCATED AT 250 WORDS)

Early stage primary bone lymphoma - a retrospective, multicenter rare cancer network (rcn) study

Purpose: Primary bone lymphoma (PBL) accounts for less than 1% of all malignant lymphomas, and 4-5% of all extra-nodal lymphomas. In this study, the disease profile, outcome, and prognostic factors were assessed in patients with stage I and II PBL.Patients and Methods: Thirteen Rare Cancer Network (RCN) institutions enrolled 116 consecutive patients with PBL treated between 1987 and 2008 in this study. Inclusion criteria were age > 16 years, stage I and II, minimum 6 months follow-up and a biopsy-proven confirmation of non-Hodgkin's lymphoma (NHL). Eighty-seven patients underwent chemoradiotherapy (CXRT), 15 radiotherapy (RT) without (13) or with (2) surgery, 14 chemotherapy (CXT) without (9) or with (5) surgery. Median RT dose was 40 Gy (range: 4-60). The median number of CXT cycles was 6 (range: 2-8). Median follow-up was 41 months (range: 6-242).Results: The overall response rate at the end of treatment was 91% (CR 74%, PR 17%). Local recurrence or progression was observed in 12 (10%) patients, and systemic recurrence in 17 (15%). Causes of death included disease progression in 21, unrelated in 5, CXT-related toxicity in 1, and second primary cancer in 2 patients. The 5-yr overall survival (OS), lymphoma-specific survival (LSS), and local control (LC) were 76%, 78% and 92%, respectively. In univariate analyses (log-rank test), favorable prognostic factors for OS were age <50 years (P=0.008), international prognostic index (IPI) score ≤1 (P=0.009), high grade histology (P=0.04), CXRT (P=0.05), CXT (P=0,0004), complete response (CR) (P<0.0001), number of CXT cycles ( ≥6 ) (P=0.01), and RT dose > 40 Gy (P=0.005). All above-mentioned parameters were also significant for LSS except for age and number of chemotherapy cycles. For LC, only CR and stage I were favorable factors. In multivariate analysis, IPI score, RT dose, complete response, and chemotherapy were independently influencing the outcome (OS and LSS). Complete response at the end of treatment was the only predicting factor for LC. Six patients developed grade 3 or more toxicities, according to Common Terminology Criteria for Adverse Events (CTCAE) V3.0.Conclusion: This large multicenter study confirms the relatively good prognosis of early stage PBL treated with combined CXRT. Local control was excellent, while systemic failures were rare. An adequate dose of RT (40 Gy or more) and complete CXT regime (≥ 6 cycles) were associated with better outcome.

Produção de inoculante micorrízico on farm utilizando resíduos da indústria florestal

A produção de inoculante à base de fungos micorrízicos arbusculares (FMAs) utilizando o método on farm é uma alternativa para estimular o uso de inoculante microbiano no sistema de produção vegetal e reduzir os custos associados com a compra desse produto. O objetivo deste estudo foi avaliar o potencial de resíduos do setor florestal, a casca de Pinus (CP) e o lodo de celulose (LC), como componentes do substrato para a produção de inoculante micorrízico on farm . Plantas de sorgo pré-colonizadas com os FMAs, Claroideoglomus etunicatum RJN101A e Dentiscutata heterogama PNB102A, foram estabelecidas em casa de vegetação por três meses em substrato formado por areia:argila expandida:solo (2:2:1). Após, essas foram transplantadas para sacos plásticos de 20 L contendo substrato formado por CP ou LC, misturados com casca de arroz carbonizada + solo de barranco (1:1:1). O experimento seguiu um fatorial 2 × 2, sendo dois isolados fúngicos e dois resíduos, com cinco repetições, em delineamento inteiramente casualizado. As plantas cresceram por três meses sob condições ambientais e, após esse período, o substrato foi analisado quanto ao número de esporos de FMAs, à colonização micorrízica da planta hospedeira e ao potencial de inóculo pelo método do NMP (número mais provável). O substrato foi dividido em três camadas (superior, mediana e inferior) e apenas o número de esporos foi avaliado individualmente para cada camada. O número de esporos de ambos FMAs não foi influenciado pelo tipo resíduo, mas diminuiu da parte superior para a inferior dentro de cada unidade experimental. D. heterogama tendeu a produzir maior número de esporos do que C. etunicatum . A porcentagem de colonização micorrízica do sorgo pelos FMAs foi significativamente maior no resíduo LC do que CP. O número de propágulos infectivos de FMAs tendeu também a ser maior em LC (22 a 28 propágulos cm-3 substrato) do que em CP (1,6 a 6,5 propágulos cm-3 substrato). O resíduo LC tem potencial para ser utilizado como componente do substrato em sistemas de produção de inoculante micorrízico on farm.

Proteomic analysis of membrane rafts of melanoma cells identifies protein patterns characteristic of the tumor progression stage.

The molecular mechanisms controlling the progression of melanoma from a localized tumor to an invasive and metastatic disease are poorly understood. In the attempt to start defining a functional protein profile of melanoma progression, we have analyzed by LC-MS/MS the proteins associated with detergent resistant membranes (DRMs), which are enriched in cholesterol/sphingolipids-containing membrane rafts, of melanoma cell lines derived from tumors at different stages of progression. Since membrane rafts are involved in several biological processes, including signal transduction and protein trafficking, we hypothesized that the association of proteins with rafts can be regulated during melanoma development and affect protein function and disease progression. We have identified a total of 177 proteins in the DRMs of the cell lines examined. Among these, we have found groups of proteins preferentially associated with DRMs of either less malignant radial growth phase/vertical growth phase (VGP) cells, or aggressive VGP and metastatic cells suggesting that melanoma cells with different degrees of malignancy have different DRM profiles. Moreover, some proteins were found in DRMs of only some cell lines despite being expressed at similar levels in all the cell lines examined, suggesting the existence of mechanisms controlling their association with DRMs. We expect that understanding the mechanisms regulating DRM targeting and the activity of the proteins differentially associated with DRMs in relation to cell malignancy will help identify new molecular determinants of melanoma progression.

Combining protein identification and quantification: C-terminal isotope-coded tagging using sulfanilic acid.

Two methods of differential isotopic coding of carboxylic groups have been developed to date. The first approach uses d0- or d3-methanol to convert carboxyl groups into the corresponding methyl esters. The second relies on the incorporation of two 18O atoms into the C-terminal carboxylic group during tryptic digestion of proteins in H(2)18O. However, both methods have limitations such as chromatographic separation of 1H and 2H derivatives or overlap of isotopic distributions of light and heavy forms due to small mass shifts. Here we present a new tagging approach based on the specific incorporation of sulfanilic acid into carboxylic groups. The reagent was synthesized in a heavy form (13C phenyl ring), showing no chromatographic shift and an optimal isotopic separation with a 6 Da mass shift. Moreover, sulfanilic acid allows for simplified fragmentation in matrix-assisted laser desorption/ionization (MALDI) due the charge fixation of the sulfonate group at the C-terminus of the peptide. The derivatization is simple, specific and minimizes the number of sample treatment steps that can strongly alter the sample composition. The quantification is reproducible within an order of magnitude and can be analyzed either by electrospray ionization (ESI) or MALDI. Finally, the method is able to specifically identify the C-terminal peptide of a protein by using GluC as the proteolytic enzyme.

SARM-S4 and metabolites detection in sports drug testing: a case report.

Recently, pharmaceutical industry developed a new class of therapeutics called Selective Androgen Receptor Modulator (SARM) to substitute the synthetic anabolic drugs used in medical treatments. Since the beginning of the anti-doping testing in sports in the 1970s, steroids have been the most frequently detected drugs mainly used for their anabolic properties. The major advantage of SARMs is the reduced androgenic activities which are the main source of side effects following anabolic agents' administration. In 2010, the Swiss laboratory for doping analyses reported the first case of SARMs abuse during in-competition testing. The analytical steps leading to this finding are described in this paper. Screening and confirmation results were obtained based on liquid chromatography tandem mass spectrometry (LC-MS/MS) analyses. Additional information regarding the SARM S-4 metabolism was investigated by ultra high-pressure liquid chromatography coupled to quadrupole time-of-flight mass spectrometer (UHPLC-QTOF-MS).

Horae secundum usum romanum.

F. A-B. Bifolium contenant la fin de l’office du Saint Esprit ; cf. le même texte aux ff. 156-156v. XVe siècle. Copie inachevée dont les initialesont été laissées en blanc. Le f. B réglé est blanc. La justification est la même que celle du corps du manuscrit.F. 1-12v. Calendrier écrit à l’encre rouge et bleue et à l’or: nombreux saints méridionaux, en particulier de la vallée du Rhône et du Languedoc : « Fulcrani ep. [Lodevensis] » (13 févr.) ; « translatio s. Pauli » (20 février) ; « translatio s.Augustini » (28 février) ; « Pauli archi. Narbo[nensis] » (22 mars) ; « translatio b. Ferreoli [ ?] (1er avril) ; « Baudilii mart. [Nemausiensis] (20 mai) ; « Quiterie (21 mai) ; « Eutropii [ep. Arausicani] (27 mai) ; « translatio s. Saturnini » (22 juin) ; « Petri de Lucemburgo » (5 juillet) ; « Roqui mart. [Montispessulani] » (16 août) ; « Ludovici regis fratris [ep. Toletani]» (19 août) ; « Privati conf. [ep. Gabalitanus (Gévaudan)] » (21 août) ; « Fereoli mart. [Viennae] (18 sept.) ; « Apolinaris ep. [Valentinensis] » (10 oct.) ; « Firmini ep. [Ucetensis] » (11 oct.] ; « Florencii ep. [Arausicani] » (17 oct.] ; « Amancii ep. [Ruthenensis] » (5 nov.) ; « Restituti ep. [Tricastini] » (8 nov.) ; « Rufi ep. [Avenionensis] » (14 nov.) ; « Pauli ep. [Narbonensis] » (11 déc.) ; « Dominici conf. [de Silos] » (20 déc.). Mentions zodiacales et de comput, parmi lesquelles on note une « renovatio indicionum », le 24 septembre. F. 13-17. Extraits des quatre Evangiles : Io (13-14) ; Lc (14-15) ; Mt (15-16v) ; Mc (16v-17).F. 17v-71. [Horae beatae Mariae virginis secundum usum romanum]. [Ad matutinas], psaumes répartis selon les jours de la semaine (18-32v) ; — « In laudibus » (32v-42v) ; — « Ad primam » (43-46v) ; — « Ad tertiam » (46v-49) ; — « Ad sextam » (49v-52) ; « Ad IXa » (52-55) ; — « Ad vesperas » (55-60) ; — « Ad comple[c]torium » (60-64) ; — Antiennes, psaumes, leçons et répons pour les différents temps de l’année (64v-71) .F. 71-77v. Messe votive. « Missa beate Marie virginis ». « Salve sancta parens... » F. 78-85. Prières et hymnes. [Septem gaudia spiritualia b. Mariae virginis], incomplet des quatre premiers vers par lacune matérielle. « [Gaude flore virginali...] et sanctorum decoratum//...-... per eterna secula » (AH, XXXI, n° 198) ; « O sponsa Dei electa// Esto nobis via recta... » ; « ...Oratio. Domine Jhesu Christe qui beatissimam gloriosam virginem...-... pervenire mereamur » ; « Gaudia. Gaude virgo mater Christi// Que per aurem concepisti// ...-... perhemni gaudio. » (AH, XXIV, n° 57) ; cf. Leroquais, Livres d’heures, I, XXVI-XXVII ; « ... Oratio. Deus qui beatissimam virginem Mariam in consceptu... pervenire. Per... » ; « Gaudia beate Marie spiritualia. Gaude stirpe regis nata// Ab angelo saluta[ta]...-... et celorum mansio » (AH, XXXI, n° 182) ; « Oratio. Consolator mitissime Deus... sempiternis perfrui. Per... » ; « Alia oratio. Deus qui Gabrielem archangelum... mereamur habere. Qui... » ; « Devota oratio ad beatam virginem Mariam. Obsecro te domina... et michi famulo tuo pauperrimo N. ... » (Leroquais, Livres d’heures, II, 346-347).F. 85v blanc.F.86-91v. [Horae Trinitatis].F.91v-93v. Messe votive. « Missa de Trinitate ».F. 93v-97. « Devota oratio. Deus omnipotens propicius esto michi peccatori, custos mei omnibus diebus et horis vite mee, Deus Abraham... Omnes sancti angeli et archangeli Dei succurrite et subvenite michi peccatori... horis vite mee » ; cf. Leroquais, Livres d’heures, II, 396 ; — « O bone Jhesu illumina oculos meos ne unquam obdormiam... impietatem peccati mei » ; cf. Leroquais, Livres d’heures, I, XXX-XXXI ; — « Omnipotens, sempiterne et clementissime Deus qui Ezechie regi ... merear et optinere. Per... », à la forme masculine ; cf. Leroquais, Livres d’heures, II, 438 ; — « Oratio. Omnipotens sempiterne Deus te supplices exoramus ut celesti... consequantur. Per... » (Corpus orationum, VI, n° 4076).F. 97v blanc.F. 98-108. [Psaumes de la pénitence]. F. 108-117v. « Letania ». A noter parmi les confesseurs, la séquence inattendue de trois évêques de Toul honorés en Lorraine : « ... s. Mansuete, s. Gerarde, s. Aper ». Parmi les saintes : « ... s. Martha, s. Eulalia... s. Radegundis... ». — Oraisons diverses : « Propicius esto, parce nobis Domine... ut michi indigno famulo tuo N... exaudire digneris » ; — ... « Omnipotens sempiterne Deus miserere michi indigno famulo tuo N.... perficiat. Per... » ; — « Pie et exaudibilis domine Jhesu Christe Deus noster clementiam tuam... digneris eternam » ; cf. Leroquais, Psautiers, I, 25 ; — « Pietate tua quesumus Domine nostrorum solve vincula delictorum et intercedente pro nobis... virgine Dei genitrice Maria cum beatis apostolis tuis Petro et Paulo atque Andrea... eternam concede. Per... » (Corpus orationum, VI, n° 4227)...F. 118-145. [Officium mortuorum secundum usum romanum]F. 145-147v. Messe votive. « Missa pro omnibus fidelibus defunctis ». F. 148-151. [Horae sancti Spiritus].F. 151-153v. Messe votive. « Missa de sancto Spiritu », incomplet de la fin par lacune matérielle.F. 154-156v. [Horae omnium sanctorum], incomplet du premier feuillet.F. 156v-159v. Messe votive. « Missa de omnibus sanctis. F. 160-162v. [Horae sancti Sacramentis], incomplet du début par lacune matérielle. F. 162v-164v. Messe votive. « Missa de corpore Christi ».F. 164v-169v. Prières et hymnes. « ... salutatio sacratissimi corporis domini nostri Jhesu Christi. Ave Jhesu Christe verbum Patris filius [Virginis] agnus Dei...-... requies nostra vita perhemnis » ; cf. ms NAL 3211, 342 ; — « Alia oratio. Salve sancta caro Dei per quam salvi...-... da michi sedem justorum. Qui... » (ed. Leroquais, Livres d’heures, II, 348) ; — In elevatione corporis Christi. Anima Christi sanctifica me // Corpus Christi salva me... secula seculorum. Amen » ; (ed. Leroquais, Livres d’heures, II, 340 variantes) ; — « Alia. Ave verum corpus natum... o pia... ora pro nobis » (AH, LIV, n° 257) ; — « Alia devota oratio. Domine Jhesu Christe qui hanc sacratissimam carnem tuam... et periculis et in eternum » ; cf.ms NAL 3203, 26v ; — « Dum volueris communicare dic orationem. Omnipotens et misericors Deus ecce accedo ad sacratissimum accedo inquam infirmus ad medicum...-... tutela finalis in morte. Qui... » ; — « Alia oratio ante communionem. Domine sancte Pater, omnipotens eterne Deus, da mihi corpus et sanguinem... in infinita secula... » ; cf. Leroquais, Livres d’heures, II, 108 ; — « Post communionem. Gratias tibi ago Domine sancte pater omnipotens eterne Deus qui me peccatorem indignum famulum tuum saciare... et gaudium sempiternum... » ; cf. Leroquais, Livres d’heures, I, 51 ; — « Post communionem ad beatam Virginem. Serenissima Virgo et inclita mater nostri Jhesu Christi, sancta Maria regina celi et terre que eundem creatorem... hodie veracis [incomplet de la fin par lacune matérielle] ; cf. Leroquais, Livres d’heures, I, 156, 299.F. 170-173. [Horae sanctae Crucis], incomplet du début.F. 173-178. Messe votive. « Missa in honore sancte Crucis ». « Crucem tuam adoramus et veneramur domine Jhesu Christe, et per ipsam tuam sanctissimam recolimus passionem...-...defunctis vitam et gloriam sempiternam... » ; — « Alia oratio. Domine Jhesu Christe plasmator tocius creature, rex glorie obsecro miserere mei quia locutus sum... semper benedictus... » ; — « Alia oratio. Domine Jhesu Christe qui voluisti pro redemptione mundi nasci et circumcidi... ego miserrimus, vilissimus, nequissimus atque indignissimus peccator...-... latronem crucifixum. Qui... » ; — « Alia oratio. Precor te, piissime domine Jhesu Christe, per illam eximiam caritatem qua tu rex celestis... mihi tribuere digneris. Qui... » ; — « Alia oratio. Deus propicius esto michi peccatori. Quid est Jhesus nisi salvator ergo Jhesus per te ipsum redemptus sum... miserere michi Deus » ; — « Dic totum deinde dic oracionem. Tribulacionem nobis [sic], quesumus, Domine propicius respice... clementer averte. Per... ». F. 178-200. « ... suffragia sanctorum ». « ... de Trinitate » ; — « De sancto Michaele archangelo » ; — « De sancto Johanne Baptista » ; — « De sancto Petro et Paulo » ; — « De sancto Andrea apostolo » ; — « De sancto Johanne evangelista » ; — « De sancto Jacobo minori » ; — « Sanctorum Philippi et Jacobi » ; — « De innocentibus » ; — « De apostolis et evvangelistis » ; — « De sancto Stephano » ; — « De sancto Laurencio » ; — « De sancto Eutropio... Eutropium martyrem tuum (f. 183v)... » ; — « De sancto Georgio » ; — « De sancto Blasio » ; — « De sancto Dyonisio » ; — « De sancto Yppolito » ; — « De sancto Christophoro » ; — « De sancto Sebastiano. Omnipotens sempiterne Deus qui meritis beati Sebastiani martyris gloriosissimi quemdam pestem epydimie generalem hominibus mortiferam revocasti, presta supplicibus tuis ut qui hanc orationem super se portavit aut in domibus vel mansionibus scriptam aut alias de ea in tuo nomine memoriam habuerint sive in die aut in nocte legerint a simili a peste et morbo epydimie sub ejus confidencia ad te confugerint ipsius meritis et precibus ab ipsis peste et morbo epydimie et ab omnibus nocumentis venenosis necnon ab omnibus periculis corporis et anime atque a subitanea et improvisa morte et ab omnibus inimicis visibilibus et invisibilibus singulis diebus et noctibus horis atque momentis liberemur. Per Dominum. Pater noster. Ave Maria. Credo. Salva regina. Ave stella matutina, rosa sine spinis, cum reliquis ». — « Unius martyris communis » ; — « De martyribus communis » ; — « De sancto Martino » ; — « De sancto Nicholao » ; — « De sancto Anthonio » ; — « De sancto Lazaro » ; — « De sancto Restituto... Deus qui per merita beati Restituti confessoris atque pontificis a multorum oculis dolorem sanas, labem removes et visum clarificas... (189v-190) » ; — « Unius confessoris » ; — « De confessoribus communis » ; — « De beata Maria Magdalena prosa. Gaude pia Magdalena // Spes salutis // Vite vena // Lapsorum fiducia // Gaude dulcis advocata // ... » ; — « De beata Catherina. Gaude virgo Catherina /// Quam refecit lux divina // Ter quaternis noctibus //... » ; — « De beata Lucia » ; — « De beata Apollonia » ; — « De beata Agatha » ; — « De virginibus » ; — « De omnibus sanctis » ; — « De pace » ; — « De sancto Petro de Lucemburgo » ; le suffrage commence par la prière attribuée à s. Pierre de Luxembourg : « Deus pater qui creasti // Mundum et illuminasti // Suscipe...-... requiescant in pace. Amen » ; cf.ms NAL 3196, 152.F. 200v-204, feuillets réglés blancs.

Treatment results and prognostic factors in primary thyroid lymphoma patients: a rare cancer network study.

Background: This study analyzed prognostic factors and treatment outcomes of primary thyroid lymphoma. Patients and Methods: Data were retrospectively collected for 87 patients (53 stage I and 34 stage II) with median age 65 years. Fifty-two patients were treated with single modality (31 with chemotherapy alone and 21 with radiotherapy alone) and 35 with combined modality treatment. Median follow-up was 51 months. Results: Sixty patients had aggressive lymphoma and 27 had indolent lymphoma. The 5- and 10-year overall survival (OS) rates were 74% and 71%, respectively, and the disease-free survival (DFS) rates were 68% and 64%. Univariate analysis revealed that age, tumor size, stage, lymph node involvement, B symptoms, and treatment modality were prognostic factors for OS, DFS, and local control (LC). Patients with thyroiditis had significantly better LC rates. In multivariate analysis, OS was influenced by age, B symptoms, lymph node involvement, and tumor size, whereas DFS and LC were influenced by B symptoms and tumor size. Compared with single modality treatment, patients treated with combined modality had better 5-year OS, DFS, and LC. Conclusions: Combined modality leads to an excellent prognosis for patients with aggressive lymphoma but does not improve OS and LC in patients with indolent lymphoma.

Early Stage Primary Bone Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study

PURPOSE/OBJECTIVE(S): Primary bone lymphoma (PBL) represents less than 1% of all malignant lymphomas, and 4-5% of all extranodal lymphomas. In this study, we assessed the disease profile, outcome, and prognostic factors in patients with stage I and II PBL. MATERIALS/METHODS: Between 1987 and 2008, 116 consecutive patients with PBL treated in 13 RCNinstitutions were included in this study. Inclusion criteriawere: age.17 yrs, PBLin stage I and II, andminimum6months follow-up. The median agewas 51 yrs (range: 17-93).Diagnosticwork-up included plain boneXray (74%of patients), scintigraphy (62%), CT-scan (65%),MRI (58%), PET (18%), and bone-marrow biopsy (84%).All patients had biopsy-proven confirmation of non-Hodgkin's lymphoma (NHL). The histopathological type was predominantly diffuse large B-cell lymphoma (78%) and follicular lymphoma (6%), according to theWHOclassification. One hundred patients had a high-grade, 7 intermediate and 9 low-gradeNHL. Ninety-three patients had anAnn-Arbor stage I, and 23 had a stage II. Seventy-seven patients underwent chemoradiotherapy (CXRT), 12 radiotherapy (RT) alone, 10 chemotherapy alone (CXT), 9 surgery followed by CXRT, 5 surgery followed by CXT, and 2 surgery followed by RT. One patient died before treatment.Median RT dosewas 40Gy (range: 4-60).Themedian number ofCXTcycleswas 6 (range, : 2-8).Median follow-upwas 41months (range: 6-242). RESULTS: Following treatment, the overall response rate was 91% (CR 74%, PR 17%). Local recurrence was observed in 12 (10%) patients, and systemic recurrence in 17 (15%) patients. Causes of death included disease progression in 16, unrelated disease in 6, CXT-related toxicity in 1, and secondary cancer in 2 patients. The 5-yr overall survival (OS), disease-free survival (DFS), lymphoma- specific survival (LSS), and local control (LC) were 76%, 69%, 78%, and 92%, respectively. In univariate analyses (log-rank test), favorable prognostic factors for survival were: age\50 years (p = 0.008), IPI score #1 (p = 0.009), complete response (p\0.001), CXT (p = 0.008), number of CXT cycles $6 (p = 0.007), and RT dose . 40 Gy (p = 0.005). In multivariate analysis age, RT dose, complete response, and absence of B symptoms were independent factors influencing the outcome. There were 3 patients developing grade 3 or more (CTCAE.V3.0) toxicities. CONCLUSIONS: This large multicenter study, confirms the relatively good prognosis of early stage PBL, treated with combined CXRT. Local control was excellent, and systemic failure occurred infrequently. A sufficient dose of RT (. 40 Gy) and complete CXT regime (. 6 cycles) were associated with a better outcome. Combined modality appears to be the treatment of choice.

Monitoring of aglycons of yew glycosides (3,5-dimethoxyphenol, myrtenol and 1-octen-3-ol) as first indicator of yew presence.

The toxicity of yew (Taxus spp) is well known from ancient times and is mainly due to taxins acting as inhibitors of calcium and sodium transport across the cell membrane of cardiac myocytes. The confirmation of yew taxins in body fluids can be carried out by liquid chromatography-tandem mass spectrometry (LC-MS/MS). However, before selecting this precise but expensive technique, an orientation test should be done to ascertain yew presence as toxic agent in the organism. As the 3,5-dimethoxyphenol (3,5-DMP), myrtenol and 1-octen-3-ol appear as glycosidically bound volatile compounds and are very yew specific, the detection of 3,5-DMP and the measurement of 1-octen-3-ol / myrtenol concentration ratio constitute reliable indicators of yew presence in forensic cases. The detection of these compounds is easily performed by gas chromatography-mass spectrometry (GC-MS) (SIM) after an enzymatic hydrolysis (β-glucosidase) allowing the release of volatile compounds from yew glycosides. Copyright © 2012 John Wiley & Sons, Ltd.

Addressing trypsin bias in large scale (phospho)proteome analysis by size exclusion chromatography and secondary digestion of large post-trypsin peptides.

In the vast majority of bottom-up proteomics studies, protein digestion is performed using only mammalian trypsin. Although it is clearly the best enzyme available, the sole use of trypsin rarely leads to complete sequence coverage, even for abundant proteins. It is commonly assumed that this is because many tryptic peptides are either too short or too long to be identified by RPLC-MS/MS. We show through in silico analysis that 20-30% of the total sequence of three proteomes (Schizosaccharomyces pombe, Saccharomyces cerevisiae, and Homo sapiens) is expected to be covered by Large post-Trypsin Peptides (LpTPs) with M(r) above 3000 Da. We then established size exclusion chromatography to fractionate complex yeast tryptic digests into pools of peptides based on size. We found that secondary digestion of LpTPs followed by LC-MS/MS analysis leads to a significant increase in identified proteins and a 32-50% relative increase in average sequence coverage compared to trypsin digestion alone. Application of the developed strategy to analyze the phosphoproteomes of S. pombe and of a human cell line identified a significant fraction of novel phosphosites. Overall our data indicate that specific targeting of LpTPs can complement standard bottom-up workflows to reveal a largely neglected portion of the proteome.

Mico-cocktail validation for CYP3A and CYP2D6 assessment using a low dose of midazolam (0.075 mg) and dextromethorphan (2.5 mg)

Background/Aim: Cocktail approach is generally preferred to individual administration of probes in order to characterize the activity of multiple enzymes. However, cocktail strategy has several drawbacks such as drug-drug interactions, tolerability and toxicity. Hence, there is a need to develop cocktails using low doses of probes. Our aim was to investigate whether the simultaneous oral administration of microdoses of midazolam (MDZ) and dextromethorphan (DEM) can be used to assess the simultaneous activities of CYP3A and CYP2D6. Methods: As part of a 5 arm randomized cross-over control trial on the analgesic efficacy of oxycodone, ten healthy young non-smoking males received the following combinations of drugs: Quinidine (Q)+ ketoconazole (K) or Q+placebo (P) or K+P or P+P. In all cases MDZ (0.075 mg) and DEM (2.5 mg) were administrated 1 hour after Q, K or P. CYP2D6 and CYP3A activities were determined after urine collection during 8 hours (ratio DEM/DOR), and a blood sample (EDTA) after 30 min (ratio 1-OH-MDZ/MDZ). DEM and DOR analysis was performed using LC-fluorescence. MDZ and 1-OH-MDZ determination was performed using GC-MS. Allele's variants of CYP2D6 were detected using the AmpliChipTMCYP450 (Roche). Results: CYP2D6 genotype predicted 1 poor (PM), 1 intermediate (IM), 7 extensive (EM) and 2 ultra rapid (UM) metabolizers. A good correlation was obtained between the predicted and the measured phenotypes except for 1 EM phenotyped as UM. Two duplications for alleles *41/*41xN and *1/*2xN were detected and the two volunteers were phenotyped as UM. A potent inhibition of CYP2D6 or CYP3A4 was obtained when Q or K were used. Mean metabolic ratio DEM/DOR in P and K groups were 0.015 (±0.028) and 0.015 (±0.019). It significantly increased in Q and QK groups (0.668 (±0.676) and 0.743 (±1.038)). Mean 1-OH-MDZ/MDZ in P, Q were 2.73 (±1.05) and 2.55 (±1.40) while it significantly decreased in K and QK groups (0.11 (±0.05), 0.10 (±0.05)). Moreover, there were no statistically significant differences between QK and K sessions for CYP3A and between QK and Q for CYP2D6 which indicate that there is no interaction between the two metabolic pathways. Conclusion: Simultaneous assessment of CYP3A and CYP2D6 activities can be obtained by low oral doses (micro-cocktail) of MDZ and DEM. Specific inhibitors such as Q or K modulates selectively CYP2D6 or CYP3A activities.